30th June 2011
Spending on research into new cancer treatments has doubled over the past ten years, with the most cash being spent on the most fatal forms of the disease.
Figures from the National Cancer Research Institute (NCRI) show that its partners spent more than £500 million on cancer research in 2010.
Investment in oesophageal cancer has increased four-fold in the past decade while the amount spent on developing treatments for cancers of the lungs and pancreas has trebled.
In total, some £504 million was spent by the institute's partners last year, compared with £257 million in 2002.
Professor Dame Janet Husband, chair of the NCRI, said: "The amount spent on cancer research has risen year on year since the NCRI was formed a decade ago. This is thanks to the British public who make generous donations to cancer charities, and the commitment of government."
Most (60 per cent) of the funding received is spent on research which benefits all types of cancer. Breast, bowel and prostate cancer typically receive the highest levels of funding.
The NCRI is a UK-wide partnership between 22 organisations from government, charity and industry.
Posted by Edward Bartel
1 "Celebrating a decade of progress through partnership - the 10 year anniversary of NCRI and NCRN." NCRI, June 2011
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.